These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18595135)

  • 1. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
    Haefner M; Bluethner T; Niederhagen M; Moebius C; Wittekind C; Mossner J; Caca K; Wiedmann M
    World J Gastroenterol; 2008 Jun; 14(23):3681-92. PubMed ID: 18595135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
    Bluethner T; Niederhagen M; Caca K; Serr F; Witzigmann H; Moebius C; Mossner J; Wiedmann M
    World J Gastroenterol; 2007 Sep; 13(35):4761-70. PubMed ID: 17729398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
    Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
    Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
    BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
    Atadja P; Gao L; Kwon P; Trogani N; Walker H; Hsu M; Yeleswarapu L; Chandramouli N; Perez L; Versace R; Wu A; Sambucetti L; Lassota P; Cohen D; Bair K; Wood A; Remiszewski S
    Cancer Res; 2004 Jan; 64(2):689-95. PubMed ID: 14744786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
    Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
    Arnold NB; Arkus N; Gunn J; Korc M
    Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
    Chun SG; Zhou W; Yee NS
    Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
    Ellis L; Bots M; Lindemann RK; Bolden JE; Newbold A; Cluse LA; Scott CL; Strasser A; Atadja P; Lowe SW; Johnstone RW
    Blood; 2009 Jul; 114(2):380-93. PubMed ID: 19383971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
    Ryu JK; Lee WJ; Lee KH; Hwang JH; Kim YT; Yoon YB; Kim CY
    Cancer Lett; 2006 Jun; 237(1):143-54. PubMed ID: 16009488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
    Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
    Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
    Chien W; Lee DH; Zheng Y; Wuensche P; Alvarez R; Wen DL; Aribi AM; Thean SM; Doan NB; Said JW; Koeffler HP
    Mol Carcinog; 2014 Sep; 53(9):722-35. PubMed ID: 23475695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.